Progenity buys assets of ingestible device company Medimetrics

US biotech company Progenity has acquired patented assets of Medimetrics, a Dutch ingestible device company,  for an undisclosed price.  The acquired portfolio for ingestible device technologies includes 137 granted patents to go along with 15 pending applications in the US, Europe, Japan, and China. The Medimetrics assets will further consolidate Progenity’s intellectual property portfolio. Furthermore, […]

The post Progenity buys assets of ingestible device company Medimetrics appeared first on PharmaNewsDaily.com.

US biotech company Progenity has acquired patented assets of Medimetrics, a Dutch ingestible device company,  for an undisclosed price. 

The acquired portfolio for ingestible device technologies includes 137 granted patents to go along with 15 pending applications in the US, Europe, Japan, and China.

The Medimetrics assets will further consolidate Progenity’s intellectual property portfolio. Furthermore, the acquired portfolio is expected to place the biotech company in a leading position for developing ingestible devices, especially for the treatment for conditions of the gastrointestinal (GI) tract.

Harry Stylli – CEO and co-founder of Progenity said: “With the acquisition of Medimetrics’ assets, Progenity now holds one of the most robust ingestible device patent estates. The synergy of Medimetrics’ technology with our own should allow us to greatly advance development and commercialization of our pipeline of ingestible technologies and therapeutics. Our aim is to improve understanding, diagnosis, and treatment of gastrointestinal diseases, ultimately enabling precision medicine.”

See also  COSMIC-311 clinical trial : Exelixis enrolls patients to study cabozantinib in phase 3 thyroid cancer trial

Progenity’s portfolio now includes a wide range of technological advances like autonomous self-localization, targeted therapeutic delivery to the GI tract for topical and systemic applications, and sample collection and preservation from pre-selected GI locations.

Jeff Shimizu – director of device development at Progenity and Medimetrics former chief technology officer said: “Medimetrics’ expertise in device development and system engineering set the stage for ingestible drug delivery and sampling, even garnering CE marks for several products for clinical and commercial use. We are continuing to demonstrate the potential of ingestible technologies to improve the overall standard of care for gastrointestinal health.”

See also  Brooklyn Immuno Therapeutics acquires IRX Therapeutics' assets for cytokine-based cancer therapy

According to Progenity, its ingestible technologies can help diagnose and treat GI tract disorders like small intestinal bacterial overgrowth (SIBO) and inflammatory bowel disease (IBD) by offering clinicians a noninvasive option.

Related posts

See also  US biopharma company Longevity Biomedical to go public via Denali Capital

The post Progenity buys assets of ingestible device company Medimetrics appeared first on PharmaNewsDaily.com.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

Related Posts

CATEGORIES
Share This